<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Lanadelumab_Renewal_DiscontinuationCriteria_Q2</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>1) Inadequate Response: No reduction (50% or greater) in the average number of HAE attacks per month for which acute injectable treatment was received during the first three months of treatment with lanadelumab, OR</questionText>
        <status>Active</status>
        <versionNumber>2</versionNumber>
    </assessmentQuestionVersion>
    <dataType>Checkbox</dataType>
    <developerName>Lanadelumab_Renewal_DiscontinuationCriteria_Q2</developerName>
    <name>Lanadelumab_Renewal_DiscontinuationCriteria_Q2</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
